Xiaoxi Zhou

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Yang Cao, Jia Wei, Liang Zou et al. · Journal of Allergy and Clinical Immunology · 2020 · 475 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

Na Wang, Xuelian Hu, Wenyue Cao et al. · Blood · 2019 · 264 citations · Full text

Medicine, Hematology, Immunology +12

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Di Wang, Jue Wang, Guang Hu et al. · Blood · 2021 · 210 citations · Full text

Medicine, Oncology, Cancer Pharmacology +10

Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion

Xiaoyuan Huang, Xiangyang Bai, Yang Cao et al. · The Journal of Experimental Medicine · 2010 · 157 citations · Full text

Life Sciences, Immunology, Oncology +17

Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis

Yang Cao, Xiaoxi Zhou, Xiaoyuan Huang et al. · PLoS ONE · 2013 · 146 citations · Full text

Medicine, Immunology, Oncology +17